Episode
For Oncology Nurses: Relapsed/Refractory Multiple Myeloma — Proceedings from the 2026 Annual ONS Congress
- Podcast
- Hematologic Oncology Update
- Published
- Aug 3, 2026
- Duration seconds
- 5203
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/hematologic-oncology-update-916423/episodes/for-oncology-nurses-relapsed-refractory-multiple-myeloma-proceedings-from-the-2026-annual-ons-congress/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/hematologic-oncology-update-916423/for-oncology-nurses-relapsed-refractory-multiple-myeloma-proceedings-from-the-2026-annual-ons-congress.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Featuring perspectives from Dr Beth Faiman, Dr Natalie S Callander, Dr Hans Lee and Dr Mary Steinbach, moderated by Dr Callander, including the following topics: Introduction (00:00) Role of Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory (R/R) MM (3:44) Role of BCMA- and Non-BCMA-Targeted Bispecific Antibodies in R/R MM (27:00) Utility of Belantamab Mafodotin in R/R MM (49:29) Potential Role of Cereblon E3 Ligase Modulators in MM (1:07:01) CME information and select publications